|
|
|
| home > ebr > Winter 2015 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
Editor’s Letter
In light of the Ebola outbreak, Deborah O’Neil reminds us just what our industry is capable of, as well as reflecting on a number of this edition’s features.
|
|
|
|
Human Airway Epithelium
Hold Your Breath
Air-liquid interface culture models can provide a powerful platform in preclinical drug development for various respiratory diseases. Samuel Constant, Song Huang and Ludovic Wiszniewski at Epithelix and Christophe Mas at OncoTheis explore further.
|
|
|
|
|
Fluorinated Pharmaceuticals
Synthesis and Opportunity
As fluorinated active pharmaceutical ingredients continue to be introduced into the marketplace, Graham Sandford at Durham University and Cormac Murphy at University College Dublin examine the technology.
|
|
|
|
|
Molecular Biomarkers
Mental Change
Efforts in the field of mental illness could lead to novel therapeutic targets and the individualisation of patient strategies. Paul C Guest at Cambridge University reflects on how considering schizophrenia as a whole body disease may result in better treatment approaches.
|
|
|
|
Biomanufacturing Strategies
Keep it Flexible
Accinov’s Sylvain Peyrache and Agnes Nagy contemplate the effect biologics are having on the biopharmaceutical industry. With the recent progression of technology, new solutions are allowing companies to implement biomanufacturing strategies far more easily according to regulation requirements and project timelines.
|
|
|
Cell-Based Therapeutics
Heading For Market
Stefanos Theoharis from apceth GmbH maintains that it is imperative to keep in mind the various end-goals when developing cell-based therapeutics. This will position the final product well in the marketplace of tomorrow, and deliver real benefit to patients in need.
|
|
|
Biopharmaceutical Manufacturing
Synthetic Biology
Dominik Schelshorn, Sanda Ljubicic, Imre Berger and Daniel Fitzgerald of Geneva Biotech contemplate the new era of synthetic biology, and how the rapid advance of tools and technologies is changing the way we produce biopharmaceuticals.
|
|
|
|
Case Study: Schistosomiasis
Positive Action
Schistosomiasis is one of the most prevalent – yet often neglected – parasitic diseases. Elly Kourany-Lefoll, Jennifer Keiser and Remco de Vrueh at the Pediatric Praziquantel Consortium explain how a recent collaboration hopes to formulate readily administrable treatments.
|
|
|
Q&A: Vaccine Insight
Developing Immunity
Frost & Sullivan’s Aish Vivekanandan guides EBR through the hurdles of vaccine development and the impact of Ebola, before discussing what we can expect from the next decade of research.
|
|
|
|
Active Immunotherapy
Fighting Fit
Research has shown the potential for targeted immunotherapy in non-infectious diseases, specifi cally in the prevention and management of non-small-cell lung cancer. Bioven’s Erik D’Hondt and Pangaea Biotech’s Jordi Bertran-Alamillo and Jordi Codony-Servat comment on recent clinical trial results.
|
|
|
Radioimmunotherapy
Alpha, Better
Treating cancer is not a one-size-fits-all proposition. Kaushik Dave and Dragan Cicic from Actinium Pharmaceuticals Inc run through the latest developments in radioimmunotherapy and the promising effects of alpha-emitters in reducing cancerous cells.
|
|
|
Oncology Studies
Put to the Test
SMS-oncology’s Lindy Bosch and Raymond Hoffmans look at the components typically comprising a Phase 1 oncology study, describing characteristics such as sponsor types, drugs used, dose levels and patient stratification, as well as overall trial objectives.
|
|
|
|
Event Review: Crystallography
Crystal Clear
Following on from 2014 – the Year of Crystallography –EBR’s Emma Naks reviews photographer Max Alexander’s exhibition, Illuminating Atoms, which captured crystallography experiments in action, as well as displaying portraits of modern day crystallographers
|
|
|
|
Funding Models
Destination Europe
Poul Sørensen and Emil Pot of European Biopharmaceutical Enterprises comment on Europe’s sluggish R&D output, and recommend mobilising investment to encourage innovative entrepreneurship as a means of boosting economic growth.
|
|
|
In Brief
Crouching Tiger
Emile Bellott casts his mind east and asks: will China have multinational pharma companies of its own? And how will they compare to those in Europe and America?
|
|
|
|
Intellectual Property Act
Right of Way
Jasnoop Cheema at Greenaway Scott assesses the UK’s Intellectual Property Act, outlining how the latest changes hope to simplify the current patenting process and encourage growth in the life sciences sector.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Dempsey Demystifies Regulatory Cycle at DIA Europe
March 22, 2018 (Hartford, Conn.) – RWS Life Sciences Managing Director,
Sheena Dempsey, will present “Demystifying the Multilingual Complexities
in the Regulatory Cycle” at DIA Europe 2018, on April 17, at 3:30PM
(CET), in Basel, Switzerland.
More info >> |
|
 |
White Papers |
 |
|
ConsulTech GmbH
ConsulTech GmbH
ConsulTech is a consulting company founded in 1992. Since then, we have
been supporting biotech-nology, pharmaceutical and medical technology
companies as well as research institutions with the entire process of
setting-up and executing proposals for R&D projects. In projects
funded by the European Commission, ConsulTech supports the coordinator
by resuming administrative tasks allow-ing coordinators and partners to
fully concentrate on the scientific and technical success of the
pro-ject. We solve financial and administrative issues, organise
meetings, take care of the timely delivery of milestones and reports and
much more.
More info >> |
|
 |
Industry Events |
 |
BioPharm America 2018
5-6 September 2018, Hynes Convention Center
BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development.
More info >> |
|
|
